Zacks Investment Research
15 Jul 2026, 15:46 UTC · 11w ago
Verdict
Headline takes no side. We score ABBV +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
4 claims · scored −1 bearish … +1 bullish
AbbVie expects combined sales of Skyrizi and Rinvoq to exceed $31 billion in 2026, reflecting over 20% growth.
More positive than 93% of claims this week
AbbVie has acquired Apogee Therapeutics to strengthen its business development and investment case.
Continue reading
5 related stories
Top 1 mover · tap to explore
More positive than 79% of claims this week
Rinvoq is pursuing five new indications, with potential approvals for vitiligo and alopecia areata in 2026/early 2027.
More positive than 66% of claims this week
Humira sales continue to decline due to loss of exclusivity and biosimilar erosion.
So whatThe loss of a product that once accounted for over 50% of revenue remains a fundamental headwind.
More negative than 78% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Strong post-Humira growth strategy, better-than-expected financial performance, and success with Skyrizi and Rinvoq.
More positive than 76% of ticker scores this week
Positive sentiment derived from being acquired by AbbVie, strengthening the investment case.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
+7.3%
Price agrees with the score
$262.67 vs $244.78 close before publication (Jul 14) · not market-adjusted
ABBV chart →
